-
Graves病又称弥漫性甲状腺肿,属自身免疫性甲状腺疾病的一种,常伴发甲状腺功能亢进,并且患者可产生甲状腺过氧化物酶抗体(thyroid peroxidase antibody,TPOAb)和甲状腺球蛋白抗体(thyroglobulin antibody,TGAb)等甲状腺自身免疫性抗体。高浓度抗体易导致Graves病的复发[1],近年来,有少量研究报道补硒能降低患者血清TPOAb、TGAb的水平[1-2],而补硒对经131I治疗后的Graves病患者TPOAb水平的影响报道很少,本研究旨在观察Graves病经131I治疗后,补硒对患者血清TPOAb水平的影响。
-
治疗后6个月,两组TPOAb水平较治疗前明显升高(对照组:Z=-2.084,P < 0.05;硒治疗组:Z=-2.112,P < 0.05),但组间比较差异无统计学意义(Z=-0.764,P > 0.05);治疗后12个月,对照组TPOAb水平较治疗前无明显变化(Z=-1.538,P > 0.05),硒治疗组TPOAb水平较治疗前明显降低(Z=-5.465,P < 0.01),组间比较差异有统计学意义(Z=-2.180,P < 0.05),硒治疗组TPOAb水平降低明显低于对照组;两组治疗前及治疗后TPOAb阳性率差异无统计学意义(对照组:X21=0.720、X22=0.103,P > 0.05;硒治疗组:X21=0.023、X22=0.340,P > 0.05)(表 1)。对TPOAb水平进行分组,从表 2可以看出,治疗后12个月,硒治疗组TPOAb阴性比例未见明显增加,但TPOAb水平为61~450 IU/ml的患者比例明显增加,901~1300 IU/ml的患者比例明显减少,而对照组变化不明显。
组别及时间点 例数 TPOAb水平(IU/ml) TPOAb阳性率 对照组 112 治疗前 342.0 78.6%(88/112) 治疗后6个月 906.5 83.0%(93/112) 治疗后12个月 232.5 76.8%(86/112) 硒治疗组 154 治疗前 450.0 82.5%(127/154) 治疗后6个月 1 087.0 83.1%(128/154) 治疗后12个月 180.0 79.9%(123/154) 表中,TPOAb:甲状腺过氧化物酶抗体。 表 1 对照组和硒治疗组治疗前后TPOAb水平和TPOAb阳性率比较
Table 1. Comparison of positive rate of TPOAb and TPOAb levels before and after treatment between control group and selenium group
组别及时间点 TPOAb分组IU/ml) 合计 0~60 61~450 451~900 901~1300 对照组 治疗前 24 38 8 42 112 6个月后 19 18 14 61 112 12个月后 26 42 14 30 112 硒治疗组 治疗前 27 52 15 60 154 6个月后 26 26 21 81 154 12个月后 31 85 22 16 154 表中,TPOAb:甲状腺过氧化物酶抗体。 表 2 对照组和硒治疗组治疗前后患者血清 TPOAb 水 平分组情况 (例)
Table 2. Grouping of serum TPOAb levels in both control group and selenium group after and before treatment
硒对经131I治疗Graves病患者血清甲状腺过氧化物酶抗体水平的影响
Effect of additional selenium on the levels of serum thyroid peroxidase antibody in patients with Graves disease treated with 131I
-
摘要:
目的 探讨Graves病患者经131I治疗后,补硒对患者血清甲状腺过氧化物酶抗体(TPOAb)水平的影响。 方法 选取TPOAb水平为10~1300 IU/ml的Graves病患者266例,其中,TPOAB范围在10~60 IU/ml为阴性,TPOAb > 60 IU/ml为阳性。将所有患者随机分成对照组(112例)和硒治疗组(154例),对照组经131I治疗后行常规治疗,硒治疗组经131I治疗后行常规治疗及服硒制剂(100 μg/次,2次/d),比较两组治疗后6、12个月TPOAb水平及TPOAb阳性率的变化。 结果 治疗后6个月,两组TPOAb水平较治疗前均明显上升,且差异有统计学意义(对照组:Z=-2.084,P < 0.05;硒治疗组:Z=-2.112,P < 0.05),但两组之间的差异无统计学意义(Z=-0.764,P>0.05);治疗后12个月,对照组TPOAb水平与治疗前相比差异无统计学意义(Z=-1.538,P>0.05),硒治疗组TPOAb水平与治疗前相比差异有统计学意义(Z=-5.465,P < 0.01),两组间比较差异有统计学意义(Z=-2.180,P < 0.05);两组TPOAb水平阳性率在治疗后6、12个月与治疗前相比无明显变化(对照组:x12=0.720、x22=0.103,P均>0.05;硒治疗组:x12=0.023、x22=0.340,P均>0.05),两组间比较差异亦无统计学意义(x12=0.001、x22=0.366,P均>0.05)。 结论 结论补硒能有效降低经131I治疗的Graves病患者的血清TPOAb水平,对血清高水平TPOAb的降低尤为明显。 -
关键词:
- 硒 /
- 碘放射性同位素 /
- 格雷夫斯病 /
- 甲状腺过氧化物酶抗体
Abstract:Objective To explore the effect of additional selenium on the serum levels of thyroid peroxidase antibody(TPOAb) after treatment of Graves disease with 131I. Methods A total of 266 patients with TPOAb levels between 10 and 1300 IU/ml participated in this study. TPOAb levels within 10 IU/ml to 60 IU/ml were considered negative, and levels greater than 60 IU/ml were considered positive. All patients were randomly divided into control(n=112) and selenium treatment group(n=154). After treatment with 131I, the control group received conventional therapy, whereas the selenium treatment group received additional selenium(100 μg twice a day). The TPOAb levels and positive ratios of the two groups were compared with pre-therapy levels after treatment for 6 and 12 months. Results After 6 months, the TPOAb levels in both groups significantly increased compared with the pre-therapy levels(control group:Z=-2.084, P < 0.05; selenium treatment group:Z=-2.112, P < 0.05). However, no significant difference existed in the TPOAb levels between the two groups(Z=-0.764, P > 0.05). After 12 months, the TPOAb levels in the control group did not change significantly compared with the pre-therapy levels(Z=-1.538, P > 0.05), whereas the TPOAb levels in the selenium treatment group significantly decreased compared with the pre-therapy levels(Z=-5.465, P < 0.01). The difference between the two groups were statistically significant(Z=-2.180, P < 0.05). The positive ratios of TPOAb for both groups did not change significantly 6 or 12 months after 131I therapy(control group:x12= 0.720, x22=0.103, both P > 0.05; selenium treatment group:x12=0.023, x22=0.340, both P > 0.05). Overall, the positive ratios were not statistically significant between the two groups(x12=0.001, x22=0.366, both P > 0.05). Conclusion Additional treatment with selenium after 131I therapy for Graves disease can effectively decrease the TPOAb levels, especially for patients with high initial TPOAb levels. -
Key words:
- Selenium /
- Iodine radioisotopes /
- Graves disease /
- Thyroid peroxidase antibody
-
表 1 对照组和硒治疗组治疗前后TPOAb水平和TPOAb阳性率比较
Table 1. Comparison of positive rate of TPOAb and TPOAb levels before and after treatment between control group and selenium group
组别及时间点 例数 TPOAb水平(IU/ml) TPOAb阳性率 对照组 112 治疗前 342.0 78.6%(88/112) 治疗后6个月 906.5 83.0%(93/112) 治疗后12个月 232.5 76.8%(86/112) 硒治疗组 154 治疗前 450.0 82.5%(127/154) 治疗后6个月 1 087.0 83.1%(128/154) 治疗后12个月 180.0 79.9%(123/154) 表中,TPOAb:甲状腺过氧化物酶抗体。 表 2 对照组和硒治疗组治疗前后患者血清 TPOAb 水 平分组情况 (例)
Table 2. Grouping of serum TPOAb levels in both control group and selenium group after and before treatment
组别及时间点 TPOAb分组IU/ml) 合计 0~60 61~450 451~900 901~1300 对照组 治疗前 24 38 8 42 112 6个月后 19 18 14 61 112 12个月后 26 42 14 30 112 硒治疗组 治疗前 27 52 15 60 154 6个月后 26 26 21 81 154 12个月后 31 85 22 16 154 表中,TPOAb:甲状腺过氧化物酶抗体。 -
[1] 朱翠颜, 王筱菁, 邓承宗.硒对弥漫性毒性甲状腺肿自身免疫抗体的影响[J].吉林医学, 2013, 34(16):3147-3148.
[2] 姜云生.硒酵母治疗桥本病100例分析[J].吉林医学, 2014, 35(11):2303-2304.
[3] Mariotti S, Caturegli P, Piccolo P, et al. Antithyroid peroxidase autoantibodies in thyroid diseases[J]. J Clin Endocrinol Metab, 1990, 71(3):661-669. doi: 10.1210/jcem-71-3-661 [4] Rayman MP. Selenium and human health[J]. Lancet, 2012, 379(9822):1256-1268. doi: 10.1016/S0140-6736(11)61452-9 [5] Fairweather-Tait SJ, Bao YP, Broadley MR, et al. Selenium in human health and disease[J]. Antioxid Redox Signal, 2011, 14(7):1337-1383. doi: 10.1089/ars.2010.3275 [6] Duntas LH. Selenium and the thyroid:a close-knit connection[J]. J Clin Endocrinol Metab, 2010, 95(12):5180-5188. doi: 10.1210/jc.2010-0191 [7] 刘莉, 平智广, 朱本章.自身免疫性甲状腺病患者血清硒水平[J].中华内分泌代谢杂志, 2005, 21(6):537-538.
[8] 屈伟, 王社教, 封娟毅, 等. Graves甲亢患者131碘治疗后血清TPOAb、TGAb抗体变化的临床意义[J].陕西医学杂志, 2010, 39(2):205-207.
[9] Turker O, Kumanlioglu K, Karapolat I, et al. Selenium treatment in autoimmune thyroiditis:9-month follow-up with variable doses[J]. J Endocrinol, 2006, 190(1):151-156. [10] Duntas LH, Mantzou E, Koutras DA. Effects of a six month treatment with selenomethionine in patients with autoimmune thyroiditis[J]. Eur J Endocrinol, 2003, 148(4):389-393. doi: 10.1530/eje.0.1480389 [11] Gärtner R, Gasnier BC, Dietrich JW, et al. Selenium supplementation in patients with autoimmune thyroiditis decreases thyroid peroxidase antibodies concentrations[J]. J Clin Endocrinol Metab, 2002, 87(4):1687-1691. doi: 10.1210/jcem.87.4.8421 [12] Anastasilakis AD, Toulis KA, Nisianakis P, et al. Selenomethionine treatment in patients with autoimmune thyroidifis:a prospective quasi-randomised trial[J]. Int J Clin Pratt, 2012, 66(4):378-383. doi: 10.1111/j.1742-1241.2011.02879.x [13] 朱琳, 白雪, 滕卫平, 等.硒对自身免疫性甲状腺炎自身抗体的影响[J].中华医学杂志, 2012, 92(32):2256-2260.